BOC Sciences Releases High-Standard GalNAc-siRNA Conjugation Services to Support siRNA Drug Delivery to Liver

New York, USA - December 29, 2022 - BOC Sciences today announced the release of premium GalNAc-siRNA conjugation services to further support the delivery of siRNA drugs to the liver.

N-Acetylgalactosamine (GalNAc) is an amino sugar derivative of galactose and can be used as a targeting ligand in antisense oligonucleotides (ASO) and siRNA therapeutics. Meanwhile, the asialoglycoprotein receptor (ASGR) is an ideal hepatocyte-specific candidate for targeted drug delivery due to its high capacity for substrate clearance from serum via receptor-mediated endocytosis and high hepatocyte expression that conserved across species. Mechanistically, GalNAc binds to the ASGR receptor to activate receptor-mediated endocytosis rapidly. So, conjugation of GalNAc has become a major strategy for the delivery of oligos to hepatocytes.

As a comprehensive manufacturer of chemicals in the preclinical stage, BOC Sciences leverages its wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help researchers make best-informed decisions tailored to their evolving needs for premium chemicals. To enhance the delivery capability of siRNA candidate drugs to target cells, BOC Sciences' expert team can design and synthesize siRNAs based on targeting receptors while combining GalNAc molecules to form GalNAc-siRNA conjugates. Not to mention the GalNAc-siRNA targeting strategy has become a relatively simple solution for siRNA drug delivery to the liver and has shown improved tissue-specific delivery and efficacy in ASO and siRNA areas.

Meanwhile, BOC Sciences provides one-stop fermentation services to manufacture oligonucleotides and nucleic acids (such as plasmid DNA). Its scientific team can personalize fermentation process solutions according to the target product requirements and requested fermentation scales. After years of development, the company has established large-scale fermentation tanks of different volumes, ranging from 4,000 L to 12,000 L, with a total of over 100,000 L capability, all to meet the different needs of researchers for their scientific projects.

"Utilizing the power of RNAi molecules, we have developed different GalNAc-siRNA conjugates for efficient drug delivery to targeting receptors, including hard-to-transfect cells. Based on our well-established scale-up fermentation platform, our experts can provide international clients with high-standard siRNA products through comprehensive fermentation strategies. We are confident in providing high-quality service to facilitate our clients' GalNAc-siRNA therapeutics development." The marketing manager at BOC Sciences said.

About BOC Sciences

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. The company has been supplying high-quality products for its esteemed customers in academia, pharmaceuticals, biotech, CDMO, material sciences, and agriculture to support research and production needs. In addition, the company works closely with synthetic laboratories, fermentation labs, OMs, and global partners and proudly offers a full range of product portfolios.

Media Contact
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1-631-485-4226
Country: United States
Website: https://www.bocsci.com